Literature DB >> 10531185

Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease.

A E Bakst1, S P Gaine, L J Rubin.   

Abstract

Gaucher's disease is a rare disorder characterized by a deficiency of lysosomal beta-glucosidase. Pulmonary hypertension, the etiology of which is unclear, has been reported to occur in association with Gaucher's disease. We report the use of continuous intravenous epoprostenol (prostacyclin), which has been used to treat other forms of pulmonary hypertension, in a patient with pulmonary hypertension associated with Gaucher's disease. Although its mechanism of action remains unknown, epoprostenol may be an effective form of therapy for chronic pulmonary hypertension due to a variety of conditions, one of which is Gaucher's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10531185     DOI: 10.1378/chest.116.4.1127

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

Review 1.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

2.  Macitentan in the treatment of pulmonary hypertension in Gaucher‚s disease.

Authors:  Gokay Taylan; Meryem Aktoz; Mehmet Celik; Mustafa Yılmaztepe
Journal:  Anatol J Cardiol       Date:  2020-01       Impact factor: 1.596

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.